Core Viewpoint - ST Bailin has successfully applied to remove other risk warnings, allowing it to "delist" from the ST designation and resume normal trading conditions [2][3] Group 1: Company Announcement - ST Bailin's stock will be suspended for one day on June 27 and will resume trading on June 30, 2025, with its name changing from "ST Bailin" to "Guizhou Bailin" [2] - The daily price fluctuation limit will increase from 5% to 10% following the removal of risk warnings [2] Group 2: Internal Control and Financial Performance - In 2023, ST Bailin received a negative opinion on its internal control audit report from Tianjian Accounting Firm, leading to the imposition of risk warnings [2] - For 2024, ST Bailin has received a qualified opinion on its internal control audit report, indicating that the issues from the previous year have been resolved [3] - The company reported a total revenue of 3.825 billion yuan in 2024, a year-on-year decrease of 10.26%, but achieved a net profit of 33.62 million yuan, marking a turnaround from losses [3] Group 3: Product and Market Position - ST Bailin specializes in the research, production, and sales of苗药 (苗药 refers to traditional Chinese medicine), with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup [3] - The company holds significant market shares in cardiovascular, cough, cold, and pediatric medicine sectors [3] - The "Bailing Bird" trademark products cover various medical fields and have achieved over 100 million yuan in sales in major markets [3] Group 4: Future Outlook - Following the completion of internal control reforms, ST Bailin aims to refocus on its core business, deepen reforms, and strengthen its leading position in苗药 [4] - The company plans to accelerate new drug development and market expansion for long-term stable growth [4]

Core Viewpoint - The company, Guizhou BaiLing Pharmaceutical Group Co., Ltd., has faced significant challenges in its financial performance for the year 2024, with a notable decrease in revenue and a mixed picture regarding profitability and cash flow [14][22]. Financial Performance - The company reported operating revenue of 3.825 billion yuan, a decrease of 10.26% year-on-year [14]. - The net profit attributable to shareholders was 33.62 million yuan, showing an increase compared to a net loss of 82.44 million yuan in the previous year, marking an 81.33% improvement [14][22]. - The net cash flow from operating activities was 9.02 million yuan, a significant decrease of 92.83% year-on-year [14]. Revenue Breakdown - The revenue composition for 2024 included: - Traditional Chinese medicine: 3.381 billion yuan, down 12.00% - Western medicine: 293.07 million yuan, down 0.68% - Chinese medicinal materials: 22.04 million yuan, up 30.24% - Medical services: 66.68 million yuan, up 13.21% - Others: 62.56 million yuan, up 25.57% [17]. Cost and Expense Analysis - The total operating costs were 1.603 billion yuan, down 15.88% year-on-year, primarily due to decreased sales volume [18]. - Sales expenses decreased by 19.77% to 1.854 billion yuan, reflecting cost-cutting measures [18]. - The gross profit margin improved to 58.09%, up 2.80% from the previous year, attributed to lower raw material prices [19]. Internal Control and Audit Opinions - The company received a qualified audit opinion for 2023 due to significant internal control deficiencies related to sales expense recognition [5][8]. - In 2024, the company implemented corrective measures and received a clean audit opinion with an emphasis on matters, indicating improvements in internal controls [10][11]. Customer and Supplier Concentration - The top five customers accounted for 39.13% of total sales, while the top five suppliers represented 46.05% of total purchases, indicating a high concentration risk [14][28]. Market Conditions - The pharmaceutical industry faced challenges due to decreased demand for cold and flu medications, as consumers had stocked up during previous health crises [17]. - The overall market for pharmaceutical products has seen price reductions, contributing to the revenue decline [17]. Quarterly Performance Fluctuations - The company experienced significant fluctuations in quarterly performance, with the first and fourth quarters showing higher revenues due to seasonal demand for cold and flu medications [25][26]. - The cash flow from operating activities was notably negative in the first and third quarters, primarily due to delayed receivables [27]. Conclusion - The company is navigating a challenging financial landscape with a focus on improving internal controls and addressing revenue declines through strategic adjustments in operations and cost management [14][22].

Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. received an inquiry letter from the Shenzhen Stock Exchange regarding its 2024 annual report, highlighting issues related to the audit opinion and internal control deficiencies [1][2]. Financial Performance - The company reported a revenue of 3.825 billion yuan in 2024, a decrease of 10.26% year-on-year. However, the net profit attributable to shareholders was 33.62 million yuan, an increase from a net loss of 82.44 million yuan in the previous year, marking an 81.33% improvement [25][26]. - The operating cash flow was 9.02 million yuan, a significant decrease of 92.83% compared to the previous year [25]. Audit Opinion - The annual auditor, Tianjian Accounting Firm, issued a qualified opinion on the 2024 financial report due to insufficient evidence regarding the realizable net value of certain raw materials and the recognition of sales expenses from the previous year [1][2][10]. - The audit highlighted two main issues: disputes over shareholding ratios with minority shareholders and ongoing investigations by the China Securities Regulatory Commission [1][2]. Inventory Valuation - The company assessed the realizable net value of its inventory, specifically a type of traditional Chinese medicine, based on a 10-year shelf life, concluding that there were no impairment signs [3][5]. - The inventory included 883.84 tons of raw materials, with a calculated impairment provision of approximately 58.38 million yuan [4][5]. Internal Control Issues - The company identified 288 million yuan in sales expenses that were not recorded in previous years, attributed to insufficient accruals and communication issues with sales offices and agents [5][6]. - Following a negative internal control audit opinion in 2023, the company implemented corrective measures, resulting in a new audit report for 2024 that indicated the elimination of previous deficiencies [16][18]. Legal Disputes - The company is involved in legal disputes regarding the shareholding of its subsidiary, He Ren Tang Pharmaceutical Co., Ltd., with ongoing litigation concerning the ownership of 40% of the shares [6][7]. - The company has taken legal action to contest a court ruling that awarded shares to a minority shareholder, and the case is currently under review [6][7]. Customer and Supplier Concentration - The top five customers accounted for 39.13% of total sales, while the top five suppliers represented 46.05% of total purchases, indicating a high concentration risk [25][26].

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. has addressed the issues raised in the 2023 internal control audit report, and the impact of the negative opinion has been eliminated, allowing the company to meet the conditions for the removal of risk warnings on its stock [3][4][6]. Group 1: Internal Control Audit Findings - The 2023 internal control audit report indicated significant deficiencies in the company's internal controls related to sales expenses, including delays in expense recognition and incomplete confirmations [6][9]. - The company has implemented a series of corrective measures to enhance internal controls and ensure compliance with relevant regulations [6][8]. Group 2: Compliance and Rectification Measures - The company has established a compliance management department and engaged third-party consulting firms to optimize internal controls and rectify deficiencies [7][8]. - Continuous training for relevant personnel has been emphasized to strengthen governance and prevent violations [8]. Group 3: Current Status and Future Outlook - As of December 31, 2024, the company maintained effective internal controls over financial reporting in all material respects [4][6]. - The company has confirmed that it does not meet any conditions that would require additional risk warnings under the Shenzhen Stock Exchange listing rules [5][6].

BEIDOUXING LAW OFFICE 贵州省贵阳市观山湖区金朱东路 399 号贵阳恒大中心 B 座 24 楼 邮编：550001 电话：86901517 传真：86901634 电子邮箱：1026333654@qq.com 贵州北斗星律师事务所 关于贵州百灵企业集团制药股份有限公司 2023 年度内部控制否定意见涉及事项影响已消除的 专项核查意见 致：贵州百灵企业集团制药股份有限公司全体股东 贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集团制药股份 有限公司（以下简称"贵州百灵"或"公司"）委托，审核了后附的贵州百灵企 业集团制药股份有限公司（以下简称贵州百灵公司）董事会编制的《关于贵州百 灵企业集团制药股份有限公司 2023 年度内部控制审计报告否定意见涉及事项影 响已消除的专项说明》（以下简称《否定意见涉及事项影响已消除的专项说明》）， 本所根据《中华人民共和国公司法》《会计法》《企业内部控制基本规范》《企业 内部控制应用指引》《企业内部控制评价指引》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等法律、行政法规、部门规章、规范 ...

ST百灵：撤销其他风险警示 6月30日股票复牌 智通财经6月26日电，ST百灵(002424.SZ)公告称，公司股票将于2025年6月27日停牌一天，于6月30日开 市起复牌并撤销其他风险警示，证券简称由"ST百灵"变更为"贵州百灵"，证券代码仍为"002424"。撤销 风险警示后，公司股票交易的日涨跌幅限制由5%变更为10%。公司内部控制缺陷已完成整改，满足撤 销风险警示的条件。但需注意，公司因涉嫌信息披露违法违规被中国证监会立案调查，调查仍在进行 中。 ...

目 录 | 关于审计意见……………………………………………………第 一、 | 1—4 | 页 | | --- | --- | --- | | 二、关于内部控制……………………………………………………第 4—7 | | 页 | | 三、关于营业收入、净利润、客户供应商……………………… 第 7—17 | | 页 | | 四、关于存货跌价…………………………………………………第 17—19 | | 页 | | 五、关于应收账款…………………………………………………第 19—24 | | 页 | | 六、关于费用支付…………………………………………………第 24—29 | | 页 | 一、请年审会计师参照《中国注册会计师审计准则问题解答第 16 号——审 计报告中的非无保留意见》的有关规定说明：（1）结合重要性水平，说明针对 非标意见有关事项所采取的主要审计程序，穿行测试、细节测试等比例是否充 分，未能获取充分、适当审计证据的原因，审计范围受到何方、何种限制，是 否已执行替代程序、利用外部专家工作的情况，替代程序仍不能满足审计要求 的原因。（2）已获取的审计证据是否已足够证明相关事项影响的重大性但不具 有广泛性，是 ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-032 贵州百灵企业集团制药股份有限公司 关于深圳证券交易所 2024 年年报问询函回复的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于近日收到深圳 证券交易所上市公司管理二部《关于对贵州百灵企业集团制药股份有限公司2024 年年报的问询函》（公司部年报问询函〔2025〕第 288 号）（以下简称"年报问 询函"）。收到年报问询函后，公司高度重视，积极组织相关部门及年审会计师 对年报问询函中涉及的问题进行逐项核查，现就年报问询函中的有关事项回复如 下： 一、天健会计师事务所（特殊普通合伙）（以下简称"年审会计师"）对你 公司 2024 年度财务报告出具保留意见并附强调事项段的审计意见。保留意见所 涉事项为年审会计师无法就某种苗药产品主要原材料可变现净值的确认以及上 年同期数中销售费用的确认和计量获取充分适当的审计证据。强调事项段所涉 事项为一是你公司与控股子公司贵州百灵企业集团和仁堂药业有限公司（以下 简称"和仁堂药业"）少数股东就和 ...

一、上期审计报告中否定意见所涉及事项 如上期审计报告中"导致否定意见的事项"段所述，贵州百灵公司在市场开 拓及促销费用等的计提方面存在时间滞后、确认不完整等情况。贵州百灵公司未 能采取有效措施确保披露的销售费用的真实性、准确性与完整性。该事项表明， 贵州百灵公司与销售费用相关的内部控制存在重大缺陷，与之相关的财务报告内 部控制失效。 二、上期审计报告中否定意见所涉及事项的消除情况 贵州百灵公司针对 2023 年发现的市场开拓及促销费用等的计提方面存在时 间滞后、确认不完整等内部控制缺陷成立整改小组,由总经理担任组长。整改小 组对 2023 年发现的内部控制缺陷进行全面梳理，制定并执行以下措施进行整改： 关于对贵州百灵企业集团制药股份有限公司 2023 年度内部控制审计报告否定意见所涉及事项 已消除情况的专项说明 天健审〔2025〕8-69 号 贵州百灵企业集团制药股份有限公司全体股东： 我们接受委托，审计了贵州百灵企业集团制药股份有限公司（以下简称贵州 百灵公司）2023 年 12 月 31 日的财务报告内部控制的有效性，并出具了否定意 见的《内部控制审计报告》（天健审〔2024〕8-341 号）（以下简称上 ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-033 贵州百灵企业集团制药股份有限公司 关于撤销其他风险警示暨停复牌的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）股 票交易于 2025 年 6 月 27 日停牌一天，于 2025 年 6 月 30 日开市起复 牌。 2、公司股票自 2025 年 6 月 30 日开市起撤销其他风险警示，证 券简称由"ST 百灵"变更为"贵州百灵"，证券代码仍为"002424"， 撤销其他风险警示后，公司股票交易的日涨跌幅限制由 5%变更为 10%。 一、股票种类、简称、证券代码、涨跌幅以及股票停复牌安排 1、股票种类：人民币普通股； 1、公司内部控制缺陷已经完成整改 2024年度公司围绕"摘帽扭亏"核心任务，全体员工在董事会的 领导下，全力开展内控整改及质量专项提升工作，采取以下整改和提 升措施： 2、股票简称：由"ST 百灵"变更为"贵州百灵"； 3、证券代码：仍为"002424"； 4、撤销其他风险警示的起始日：2025 年 6 ...